Phase 2 Study of Bevacizumab Plus Erlotinib in Patients With Advanced Hepatocellular Cancer

BACKGROUND: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are rational targets for therapy in hepatocellular cancer (HCC). METHODS: Patients with histologically proven HCC and not amenable to curative or liver directed therapy were included in this 2-stage pha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Philip, Philip A., Mahoney, Michelle R., Holen, Kyle D., Northfelt, Donald W., Pitot, Henry C., Picus, Joel, Flynn, Patrick J., Erlichman, Charles
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3896238/
https://ncbi.nlm.nih.gov/pubmed/21953248
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26556
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados